Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lymphoma 1Head and Neck Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

pembrolizumab 4aflibercept 2Nivolumab 2vocimagene amiretrorepvec 1ulixertinib 1tremelimumab 1trastuzumab biosimilar HLX02 1trametinib 1tanespimycin 1sapanisertib 1romidepsin 1relatlimab 1poly ICLC 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1gallium maltolate 1erdafitinib 1epacadostat 1entinostat 1durvalumab 1defactinib 1dabrafenib 1copanlisib 1ciforadenant 1cemiplimab 1cc-486 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Flucytosine × Lymphoid × Clear all
NCT02576665 2020-02-07

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Tocagen Inc.

Phase 1 Terminated
21 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Head and Neck Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡